Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS
Pierre Fenaux, Valeria Santini, Maria Antonietta Aloe Spiriti, et al.
Leukemia (2018) Vol. 32, Iss. 12, pp. 2648-2658
Open Access | Times Cited: 142

Showing 1-25 of 142 citing articles:

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
Pierre Fenaux, Uwe Platzbecker, Ghulam J. Mufti, et al.
New England Journal of Medicine (2020) Vol. 382, Iss. 2, pp. 140-151
Open Access | Times Cited: 449
Myelodysplastic Syndromes
Mario Cazzola
New England Journal of Medicine (2020) Vol. 383, Iss. 14, pp. 1358-1374
Closed Access | Times Cited: 369
Treatment of MDS
Uwe Platzbecker
Blood (2019) Vol. 133, Iss. 10, pp. 1096-1107
Open Access | Times Cited: 195
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial
Uwe Platzbecker, Matteo Giovanni Della Porta, Valeria Santini, et al.
The Lancet (2023) Vol. 402, Iss. 10399, pp. 373-385
Closed Access | Times Cited: 103
Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials
Uwe Platzbecker, Pierre Fenaux, Lionel Adès, et al.
Blood (2018) Vol. 133, Iss. 10, pp. 1020-1030
Open Access | Times Cited: 129
Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update
Julia Bohlius, Kari Bohlke, Roberto Castelli, et al.
Blood Advances (2019) Vol. 3, Iss. 8, pp. 1197-1210
Open Access | Times Cited: 125
Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆
Pierre Fenaux, Dagmar Haase, Valeria Santini, et al.
Annals of Oncology (2020) Vol. 32, Iss. 2, pp. 142-156
Open Access | Times Cited: 121
Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update
Julia Bohlius, Kari Bohlke, Roberto Castelli, et al.
Journal of Clinical Oncology (2019) Vol. 37, Iss. 15, pp. 1336-1351
Open Access | Times Cited: 111
Myelodysplastic syndromes: moving towards personalized management
Eva Hellström‐Lindberg, Magnus Tobiasson, Peter L. Greenberg
Haematologica (2020) Vol. 105, Iss. 7, pp. 1765-1779
Open Access | Times Cited: 108
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion–Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study
David P. Steensma, Pierre Fenaux, Koen Van Eygen, et al.
Journal of Clinical Oncology (2020) Vol. 39, Iss. 1, pp. 48-56
Open Access | Times Cited: 101
Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis
Pierre Fenaux, Jean‐Jacques Kiladjian, Uwe Platzbecker
Blood (2019) Vol. 133, Iss. 8, pp. 790-794
Open Access | Times Cited: 87
How we manage adults with myelodysplastic syndrome
Pierre Fenaux, Uwe Platzbecker, Lionel Adès
British Journal of Haematology (2019) Vol. 189, Iss. 6, pp. 1016-1027
Open Access | Times Cited: 83
Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer
Sonali M. Smith, KERRI WACHTER, Howard A. Burris, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 10, pp. 1165-1184
Open Access | Times Cited: 72
Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes
Guillermo Garcia‐Manero, Valeria Santini, António Almeida, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 13, pp. 1426-1436
Open Access | Times Cited: 62
Proposals for Revised International Working Group-European LeukemiaNet Criteria for Anemia Response in Myelofibrosis
Ayalew Tefferi, Giovanni Barosi, Francesco Passamonti, et al.
Blood (2024) Vol. 144, Iss. 17, pp. 1813-1820
Closed Access | Times Cited: 10
Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort study
Hege Kristin Gravdahl Garelius, Timothy Bagguley, Adele M. Taylor, et al.
The Lancet Haematology (2025) Vol. 12, Iss. 2, pp. e128-e137
Open Access | Times Cited: 1
Current and emerging strategies for management of myelodysplastic syndromes
Caner Saygin, Hetty E. Carraway
Blood Reviews (2020) Vol. 48, pp. 100791-100791
Closed Access | Times Cited: 55
Roxadustat for the treatment of anemia in patients with lower‐risk myelodysplastic syndrome: Open‐label, dose‐selection, lead‐in stage of a phase 3 study
David H. Henry, John A. Glaspy, Rosemary Harrup, et al.
American Journal of Hematology (2021) Vol. 97, Iss. 2, pp. 174-184
Open Access | Times Cited: 46
How I diagnose and treat chronic myelomonocytic leukemia
Mrinal M. Patnaik
Haematologica (2022) Vol. 107, Iss. 7, pp. 1503-1517
Open Access | Times Cited: 29
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)
Esther Natalie Olíva, Marta Riva, Pasquale Niscola, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 28, pp. 4486-4496
Open Access | Times Cited: 19
Roxadustat versus placebo for patients with lower‐risk myelodysplastic syndrome: MATTERHORN phase 3, double‐blind, randomized controlled trial
Moshe Mittelman, David H. Henry, John A. Glaspy, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 9, pp. 1778-1789
Open Access | Times Cited: 7
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial
M. Porta, Guillermo Garcia‐Manero, Valeria Santini, et al.
The Lancet Haematology (2024) Vol. 11, Iss. 9, pp. e646-e658
Closed Access | Times Cited: 6
Clinical effectiveness and safety of erythropoietin‐stimulating agents for the treatment of low‐ and intermediate‐1−risk myelodysplastic syndrome: a systematic literature review
Sophie Park, Peter L. Greenberg, Aylin Yücel, et al.
British Journal of Haematology (2018) Vol. 184, Iss. 2, pp. 134-160
Open Access | Times Cited: 48
Therapy for lower-risk MDS
Hetty E. Carraway, Caner Saygin
Hematology (2020) Vol. 2020, Iss. 1, pp. 426-433
Open Access | Times Cited: 43
New Approaches to Myelodysplastic Syndrome Treatment
Alexandre Bazinet, Guillermo Montalban‐Bravo
Current Treatment Options in Oncology (2022) Vol. 23, Iss. 5, pp. 668-687
Closed Access | Times Cited: 25
Page 1 - Next Page

Scroll to top